Drug Design With Structure Based Drug Design Articles & Analysis
207 news found
In the ever-evolving landscape of pharmaceutical research and development, the demand for innovative and efficient drug discovery methods is more pressing than ever. At the forefront of this demanding field is Protheragen-ING AI-Pharma, a contract research and development biotechnology company, offering cutting-edge solutions to researchers through its AI-powered drug discovery and design ...
The medical device industry is undergoing a transformative period marked by groundbreaking innovations and advanced materials. As healthcare continues to evolve, the need for devices that enhance patient outcomes while ensuring safety and reliability is more critical than ever. Among the various materials used in medical device design, polytetrafluoroethylene (PTFE tubing) has emerged as a ...
Ace Therapeutics is a preclinical contract research provider engaged in ophthalmic diseases. To help pharmaceutical partners and academic institutions overcome the challenges of low bioavailability and unsustainable drug release in drug formations for glaucoma, Ace Therapeutics is proud to announce the unveiling of its cutting-edge drug delivery system development services for the treatment of ...
CD ComputaBio, a pioneering provider of computational biology services, has recently introduced its advanced Computer-Aided Drug Design (CADD) services, revolutionizing the drug discovery landscape. ...
The design of such drug carriers also helps to overcome some of the limitations of conventional drugs such as biostability, water solubility and drug distribution in the body. ...
Investorideas.com (www.investorideas.com) Biotech Stock News Bites - Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines is one of NASDAQ's top gainers today and the stock is trending on Yahoo Finance, currently trading at $3.8955, up $1.6955 or 77.0682%. The stock had a morning high of $5.47 on volume of over 36 Million/. The Company's CEO, ...
CD Formulation has been dedicated to pharmaceutical advancements, showcasing immense expertise in the development and optimization of micro-reservoir controlled-release drug delivery systems. These innovative systems have revolutionized the way medications are administered, enhancing patient comfort and ensuring optimal therapeutic efficacy. Transdermal drug delivery systems are very popular ...
This service harnesses the power of AI to engineer antibodies with unmatched precision, paving the way for targeted therapies, personalized medicine, and cutting-edge protein drug design. Antibody-based therapies have witnessed unprecedented success in treating a wide array of diseases, from cancer to autoimmune disorders. ...
Prominent within the field of computational biology, CD ComputaBio, unveils its cutting-edge Antibody Drug Design Services and Antibody Development solutions. Driven by an unwavering commitment to advancing precision medicine, the company stands at the forefront of redefining therapeutic strategies and expediting drug discovery processes, fostering innovation within the healthcare industry. In ...
CD Computabio, a prominent provider of computational biology solutions, is excited to introduce its virtual screening service based on pharmacophore fragments. This approach is poised to revolutionize the field of drug discovery by offering researchers an efficient and cost-effective solution for identifying promising drug candidates. In the early stages of drug development, virtual screening ...
CD ComputaBio, a reputable computational service provider in the field of biology, is dedicated to supporting research and trials by offering access to the latest software, technologies, and expertise at competitive prices and with fast turnaround times for researchers. Recently, the company introduced a series of state-of-the-art services in Drug Design and Computer-Aided Drug Design (CADD) with ...
CD ComputaBio, a reliable computational biology service provider in New York, is committed to assisting research and trials, as well as providing access to the latest software, technologies, and expertise at competitive prices and with fast turnarounds for researchers. The company is pleased to announce the launch of the Protein-Small Molecule Docking service, designed to help customers quickly ...
As a widely used and trusted molecular docking software, AutoDock simplifies molecular docking simulations and improves the accuracy of drug development. This software is widely used by researchers to simulate and predict the interaction between small molecules and the protein of interest, a fundamental technique for drug discovery and development. ...
Biolojic uses its proprietary AI platform to design antibodies with new capabilities to cure disease, ushering in a new era of smart therapeutics Biolojic Tel Aviv to focus on computational design of antibodies; Boston location will focus on drug development Biolojic Design, a unique technology company pioneering computational design of human antibodies to develop smart therapeutic ...
Computational chemistry, a branch of chemistry that applies computer simulation to assist in solving chemical problems, is a heated topic in the modern scientific community. Possessing a powerful team of experts in chemistry, biology, mathematics, crystallography, and pharmacology, Alfa Chemistry focuses on combining the power of computational chemistry with a variety of research focuses on ...
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided a business update and guidance for 2023. Highlights: During the 12 months ended September 30, 2022, Eagle recorded net income of $21.3 million or $1.63 per diluted share and adjusted EBITDA of $125.6 million and non-GAAP earnings per diluted share of $7.54, a significant increase from ...
The company has recently announced the introduction of its Autodock Vina software, designed to predict the mechanism of small molecules, such as substrates or drug candidates, binding to receptors with known 3D structures. ...
This has caused the OpenMM user base, which was initially focused on the biomolecular simulation community, to expand rapidly. Currently, the user base has spread to a wide range of related fields, such as materials modeling, quantum chemistry, structural bioinformatics, chemoinformatics, artificial intelligence, and machine learning. This ...
xCures, Inc. is proud to announce their partnership with RenovoRx, a clinical-stage biopharmaceutical company that focuses on fighting cancer through localized treatment of difficult-to-treat tumors, such as pancreatic adenocarcinoma. Through this collaboration, xCures will help eligible pancreatic cancer patients access a Phase III clinical study entitled, Targeted Intra-arterial Gemcitabine vs. ...
ByxCures
LB-P8, a novel drug being developed by LISCure Biosciences, Inc. (LISCure) as a treatment for Primary Sclerosing Cholangitis (PSC), has been designated as an orphan drug by the US FDA. On December 1, 2022, the US FDA notified LISCure of the orphan drug designation of LB-P8, LISCure's microbiome novel drug, as treatment of PSC. LB-P8 is, to the best of company's knowledge, the first drug to be ...